Skip to content

Correlation Between Intestinal Microecology Imbalance and Stroke in Young Adults

Research on Correlation Between Intestinal Microecology Imbalance and the Risk and Prognosis of Stroke in Young Adults

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05113043
Enrollment
60
Registered
2021-11-09
Start date
2022-02-01
Completion date
2027-12-31
Last updated
2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhagic Stroke, Ischemic Stroke

Keywords

ischemic stroke, hemorrhagic stroke, intestinal microecology, multi-omics analysis, prognosis

Brief summary

The relationship between the intestinal microecology and stroke has become a research hotspot in neurology field today. Maintaining the balance of the intestinal microbiota are expected to bring new breakthroughs for prevention and treatment of stroke. In recent years, stroke in young adults has an increasing incidence and a considerable socioeconomic impact because of high disability rate and health-care costs. So there is an urgent need to explore the role and mechanism of intestinal microecology imbalance in stroke, especially in the development and prognosis of stroke in young people. This study aims to use multi-omics technologies, including microbial diversity, metagenomics and metabonomics, to reveal the characteristics of intestinal flora in young stroke patients, identify biomarkers for predicting outcome after stroke and early detection of young people at high risk of stroke, and to further explore the role of gut-brain axis in the pathogenesis of stroke.

Interventions

None listed

Sponsors

Shanghai 6th People's Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of acute ischemic or hemorrhagic stroke * Admission within 12 hours * Aged 18-45 years

Exclusion criteria

* History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases * Combined with tumors, inflammatory bowel disease and other digestive system diseases * Combined with serious life-threatening diseases or condition * Any antibiotics, probiotics or prebiotic treatment within 3 months * Deteriorate and die before collecting faecal samples

Design outcomes

Primary

MeasureTime frameDescription
Modified Rankin Scale scores3 months0 = No symptoms; 1 = No significant disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 = Moderate disability. Requires some help, but able to walk unassisted; 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 = Dead.

Countries

China

Contacts

CONTACTHao Chen, M.D., Ph.D.
chenhao_316@aliyun.com02164369181
STUDY_DIRECTORLixia Xue, M.D., Ph.D.

Shanghai 6th People's Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 24, 2026